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Drug resistance and hepatic dysfunction are the two major factors that limit the application of
chemotherapy for hepatocellular carcinoma (HCC). It has been reported that allicin has the hepatic
protective effect and antitumor activity. Hence allicin may be an ideal enhancer to chemotherapy
regimen of HCC. In the present study, we demonstrated that allicin enhanced 5-ﬂuorouracil (5-FU)
inducing cytotoxicity in HCC cells. In vivo experiment, combined treatment group with allicin (5 mg/kg/
d; every two days for 3 weeks) and 5-FU (20 mg/kg/d; 5 consecutive days) showed a dramatic inhibitory
effect on the growth of HCC xenograft tumors in nude mice. The co-treatment group showed highly
apoptotic level compared with 5-FU treated alone. Cells combined treatment with allicin and 5-FU
increased intracellular reactive oxygen species (ROS) level, reduced mitochondrial membrane potential
(DJm), activated caspase-3 and PARP, and down-regulated Bcl-2 compared with DMSO, allicin and 5-FU
treated alone. Moreover, the increase of activated caspase-3 and PARP was blocked by the ROS inhibitor
antioxidant N-acetyl cysteine (NAC). In conclusion, this is the ﬁrst study to demonstrate that allicin
sensitized HCC cells to 5-FU induced apoptosis through ROS-mediated mitochondrial pathway. These
results provided evidences for the combination used of allicin and 5-FU as a novel chemotherapy
regimen in HCC.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common hu-
man cancer and the second most common cause of cancer-related
deaths in the world (1). The therapy approaches of HCC have been
improved in the recent years, including liver transplantation, sur-
gical resection, radiofrequency ablation (RFA), intervention,
chemotherapy, radiotherapy, molecular targeted therapy, and bio-
therapy (2,3). Surgery remains the potentially curative therapies for
early HCC patients, and non-surgical treatments play an important
role in the therapy of advanced HCC. The use of systemicrmacological Society.
d contributed equally to this
g by Elsevier B.V. on behalf of Japa
d/4.0/).chemotherapy is limited because of the chemo-resistant in HCC
cells, instinct or extrinsic (4,5). Hence, to ﬁnd combination agents
which can enhance the cytotoxicity of traditional chemothera-
peutic regimens is of great importance.
Allicin (diallyl thiosulﬁnate), rapidly converted from allin by
allinase, is the major component present in freshly crushed garlic,
and one of the most biologically active compounds of garlic (6).
Allicin has been used in the clinic for several decades with its effect
of anti-inﬂammatory, anti-microbial, cardiovascular protection,
and immunity boost (7e9). Previous investigations have shown
that allicin exerts antitumor activity in multiple tumors such as
gastric carcinoma, breast cancer, glioblastoma and HCC, by inhib-
iting cell proliferation and inducing cell apoptosis (10,11). Notably,
allicin exhibits the chemosensitive effect of CPT-11 on the colorectal
cancer cells in vitro (12). However, in vivo efﬁcacy of its chemo-
sensitivity and potential molecular mechanism in HCC is still
unknown.nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
X. Zou et al. / Journal of Pharmacological Sciences 131 (2016) 233e240234In the present study, we explored whether sub-cytotoxic al-
licin could enhance the antitumor effect of traditional chemo-
therapy drug 5-ﬂuorouracil (5-FU) in HCC cells, both in vitro and
in vivo.2. Materials and methods
2.1. Cells and reagents
Human hepatocellular carcinoma (HCC) cell lines, SK-Hep-1 and
BEL-7402, were obtained from Cell Bank of Type Culture Collection
(CBTCC, Chinese Academy of Sciences, Shanghai, China). The cells
were maintained in Dulbecco's Modiﬁed Eagle Medium (Gibco,
Grand Island, NY) supplemented with 10% fetal bovine serum
(Gibco) at 37 C in a humidiﬁed incubator containing 5% CO2. Allicin
was purchased from Guangzhou Institute For Drug Control
(Guangzhou, China). 5-Fluorouracil, N-acetyl cysteine (NAC) were
purchased from SigmaeAldrich (St. Louis, MO, USA).2.2. Cell viability assays
Cells were plated at 1  104 cells per well in 96-well. After
overnight incubation, cells were treatedwith allicin, 5-FU alone or a
combination at the indicated concentrations. After 48 h, cell
viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma) assay. Viability rate
was calculated as follow formula: viability (%) ¼ (average OD value
of drug-treated sample/average OD value of control
sample)  100%. Agents' concentrations resulting in cell growth
inhibition of 50% (IC50) were calculated by Probit Regression
Analysis.2.3. Combined effect evaluation
Using the method proposed by Chou et al. (13), the interaction
between allicin and 5-FU was quantiﬁed on the basis of the
multiple drug-effect equation and determined by combination
index (CI) value. The combination index was evaluated by Com-
puSyn software (ComboSyn, Inc., Paramus, NJ) which is available
at http://www.combosyn.com/feature.html. The CI value <1, ¼1,
and >1 indicate synergism, additive effect and antagonism,
respectively.2.4. In vivo tumor assays
Male athymic nude mice (4e6-week) were injected subcuta-
neously into left ﬂank with 1  107 GFP-SK-Hep-1 cells. When the
tumors had reached a size of 5  5 mm2, mice were randomly
divided into 4 groups (n ¼ 5 in each group). Tumor-bearing ani-
mals were treated (i.p) either with DMSO alone (as control), allicin
alone (5 mg/kg/d; every two days for 3 weeks), 5-FU (20 mg/kg/d;
5 consecutive days) alone or with a combination of allicin and 5-
FU. The tumor mass was measured every 2 days throughout the
study. Tumor volumes were determined by a caliper and calcu-
lated according to the formula (width2  length)/2. Animals were
sacriﬁced and tumors were collected 3 h after the last injection.
The ﬂuorescence emitted by the tumor cells was imaged by a
whole-body GFP imaging system (Imagestation 2000MM; Kodak,
Rochester, Rochester, NY) to visualize the formation of the tumor.
All the in vivo experiments were performed according to our in-
stitutions' guidelines for the use of laboratory animals and
approved by the institutional Animal Care and Use Committee of
Nanfang Hospital.2.5. Annexin V-ﬂuorescein isothiocyanate (FITC)epropidium iodide
(PI) assays
Cells were incubated with allicin and 5-FU alone or in combi-
nation for 48 h, collected and suspended in 1 binding buffer.
Apoptotic cells were evaluated by Annexin V-FITC and PI Apoptosis
Detection Kit (Apoptosis Detection Kit, KeyGEN, Nanjing, China)
according to the manufacturer's protocol. Stained cells were
analyzed by FACSCanto II Flow Cytometer (BD Biosciences, San Jose,
CA). Cells that were Annexin V positive and PI negative were
considered as apoptotic cells.
2.6. Western blot analysis
Cells were lysed with RIPA buffer (Cell Signaling Technology,
Boston, MA) containing protease inhibitor (Roche, Indianapolis, IN).
Equal amounts of proteinwere separated by electrophoresis on 10%
SDS-PAGE gels and transferred onto polyvinylidene diﬂuoride
membranes (PVDF; Millipore, Bedford, MA). After blocking with 5%
nonfat dry milk in Tris-buffered saline (TBST, 100 mM NaCl, 50 mM
Tris, 0.1% Tween-20; pH 7.5), membranes were incubated with
primary antibody for caspase-3 (Abcam, Cambridge, UK), Poly
(ADP-ribose) polymerase (PARP; Abcam), Bcl-2 (Abcam), and b-
actin (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4 C.
After washing with TBST, the membranes were incubated with
corresponding secondary antibodies conjugated to horseradish
peroxidase. The signals were detected by enhanced chem-
iluminescence (ECL; Pierce, Rockford, IL).
2.7. Cellular reactive oxygen species (ROS) detection
The level of intracellular ROS was determined using Dichloro-
dihydro-ﬂuorescein diacetate assay (DCFH-DA, SigmaeAldrich).
Brieﬂy, after treatment, cells were incubated with DCFH-DA (5 mg/
mL) at 37 C for 30 min. Samples were then analyzed with Cyﬂogic
v.1.2.1 software using FITC-A band pass ﬁlter on ﬂow cytometer (BD
Bioscience).
2.8. Mitochondrial membrane potential
To detect the changes in mitochondrial transmembrane poten-
tials of cells in different treated groups, JC-1 staining was used.
After treatment, cells were trypsinized, washed twice in PBS and
suspended in mitochondrial incubation buffer (KeyGEN Biotech,
China). After adding JC-1 dye, cells were incubated at 37 C in the
dark for 15 min. Cells were washed twice in PBS and the pellet was
re-suspended in mitochondrial incubation buffer. Mitochondrial
membrane potential was determined by ﬂow cytometry (BD
Bioscience) using FL1-H (green ﬂuorescence, Ex ¼ 488 nm) and
FL2-H (red ﬂuorescence, Ex ¼ 530 nm) band pass ﬁlters.
2.9. TUNEL assay
Tumor xenografts were embedded in OCT (Sakura Finetek,
Torrance, CA), and cut into 6 mm cryopreserved sections. Tumor
tissues were stained by terminal deoxy-nucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL; In Situ Cell Death
Detection Kit, Roche). In brief, tissue sections were ﬁxed in 4%
paraformaldehyde, added permeabilisation solution, and incubated
with TUNEL reaction mixture. A minimum of three randomly
selected high-power ﬁelds containing representative sections of
each tumor were imaged. At least ﬁve tumors were examined per
treatment group. TUNEL positive cells and total cells were counted
and percent apoptotic cells calculated.
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Statistics were analyzed with the SPSS 16.0 software (Abbott
Laboratories, Chicago, IL). The quantitative data were shown asFig. 1. Allicin synergistically sensitized hepatocellular cancer cells to 5-ﬂuorouracil in vitro. (A
1, 2, 4, 8, 10, 16, 20, 32, 40, 64 mg/ml for SK-Hep-1 and 0, 1.25, 2.5, 5, 10, 20, 40, 80, 160 mg/ml
treated with different concentrations of allicin (0, 1, 2, 4, 8, 10, 16, 20, 32, 40, 64 mg/ml), and c
with various concentrations of 5-FU (0, 5, 10, 50, 100, 200, 400, 500, 800, 1000, 2000 mg/ml) f
were co-treated with allicin and 5-FU with various concentrations. Cell viability was asses
calculated by CompuSyn software (Right). Points below the dotted line indicate synergy. (*means ± SD from three independent experiments. In all experi-
ments, the signiﬁcance of the difference between groups was
calculated using one-way analysis of variance (ANOVA). A value of
P < 0.05 indicated a signiﬁcant difference.) SK-Hep-1 and BEL-7402 cells were incubated with various concentrations of allicin (0,
for BEL-7402) for 48 h, and cell viability was detected by MTT assay. (B) L02 cells were
ell viability was evaluated by MTT assay. (C) SK-Hep-1 and BEL-7402 cells were treated
or 48 h, and cell viability was evaluated by MTT assay. (D and E) SK-Hep-1 and BEL-7402
sed using MTT assay and the combination index of each combination treatment was
P < 0.05, **P < 0.01).
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4.1. Allicin synergistically sensitizes hepatocellular cancer cells to 5-
ﬂuorouracil in vitro
To explore the anti-proliferative effect of allicin and 5-FU, the
viability of HCC cells treated with allicin or 5-FU alonewas assessed
byMTTassay. As presented in Fig. 1A, allicin inhibited the growth of
SK-Hep-1 and BEL-7402 cells in a dose-dependent manner. The IC50
value of allicin was 10.389 mg/ml and 10.004 mg/ml for SK-Hep-1
and BEL-7402 cells, respectively. Allicin at the concentration un-
der 20 mg/ml had no signiﬁcant inhibiting effect on normal hepa-
tocytes indicating its safety as a chemotherapy regimen in HCC
(Fig.1B). As showed in Fig.1C, 5-FU inhibited the growth of SK-Hep-
1 and BEL-7402 cells in a dose-dependent manner. The IC50 value of
5-FU was 438.945 mg/ml and 410.336 mg/ml for SK-Hep-1 and BEL-
7402 cells, respectively. To determine the synergistic effect of allicin
and 5-FU, HCC cells were exposed to different concentration of
allicin (0, 3, 6, 10 mg/ml) and 5-FU (0, 100, 300 mg/ml) alone or in
combination, and cell viability was detected. The anti-proliferative
effect of the combined treatment was signiﬁcantly greater than that
in single agent treatment, even in subcytotoxic dose (<IC50) allicin
(Fig. 1D and E). In addition, combination index (CI) of each com-
bined treatment was analyzed and showed in the Fa-Combination
Index Plot. CI value <1 at different drug combination doses (alli-
cin 3/6/10 mg/ml with 5-Fu 100/300 mg/ml in SK-Hep-1 cells; allicin
3/6 mg/ml with 5-Fu 100/300 mg/ml and allicin 10 mg/ml with 5-Fu
300 mg/ml in BEL-7402 cells), indicated a synergistic interaction
between allicin and 5-FU both in SK-Hep-1 and BEL-7402 cells
(Table .1).4.2. Allicin enhances the chemosensitivity of 5-FU in vivo
To verify the chemotherapy sensitizing activity of allicin, a
subcutaneous xenograft tumor model was established by trans-
planting SK-Hep-1-GFP cells into nude mice. The combined
treatment group exhibited a reduced gain of tumor sizes
compared with DMSO group, allicin group, and 5-FU group
(Fig. 2A). The tumor volume and weight were also found signiﬁ-
cantly reduced in co-treated group as compared with three other
groups (P < 0.05; Fig. 2B, C). The apoptotic level of xenograft tu-
mors was much higher in co-treatment group, compared with
those in DMSO, allicin, or 5-FU treated group, as determined by
TUNEL assay (P < 0.05; Fig. 2D, E).Table 1
Fa value and combination index of combined treatments.
Cell Drug (mg/ml) Fa value Combination index
Allicin 5-Fu
SK-Hep-1 3 100 0.54 ± 0.07 0.46
6 100 0.58 ± 0.03 0.66
10 100 0.62 ± 0.05 0.86
3 300 0.54 ± 0.04 0.82
6 300 0.61 ± 0.06 0.80
10 300 0.68 ± 0.05 0.84
BEL-7402 3 100 0.47 ± 0.02 0.58
6 100 0.57 ± 0.03 0.64
10 100 0.56 ± 0.01 1.06
3 300 0.54 ± 0.03 0.56
6 300 0.57 ± 0.03 0.77
10 300 0.70 ± 0.02 0.75
Fa value is presented as the mean ± SD of three independent tests. Combination
index was calculated by using the average value of Fa derived from three inde-
pendent experiments.4.3. Subcytotoxic dose allicin enhances 5-FU induced apoptosis in
HCC cells
To investigate cellular apoptosis caused by combined treatment,
SK-Hep-1 and BEL-7402 cells treated with allicin and 5-FU alone or
in combination for 48 h and stained with Annexin V/PI followed by
Flow cytometry (FCM) analysis. As showed in Fig. 3A and B, allicin
did not increase the percentage of Annexin V-positive cells whereas
it signiﬁcantly increased 5-FU induced apoptosis in both SK-Hep-1
and BEL-7402 cells (P < 0.01). Consistent with FCM data, the ex-
pressions of apoptotic related proteins, cleaved caspase-3 and
cleaved PARP, were remarkably increased, and Bcl-2 was decreased
in combined treatment compared with 5-FU treated alone, as
determined by western blotting (Fig. 3B, C). Collectively, allicin
signiﬁcantly increased sensitivity of HCC cells to 5-FU by inducing
cellular apoptosis.
4.4. Allicin enhances 5-FU induced apoptosis through ROS-
mediated mitochondrial pathway
Previous studies have shown that allicin is involved in oxidative
stress. We speculated that allicin enhanced 5-FU-induced apoptosis
via increasing reactive oxygen species (ROS). To validate this hy-
pothesis, the ﬂuorochrome DCFH-DA was used to determine ROS
level by FCM analysis. The results showed that ROS generation was
more rapidly increased in cells co-treated by allicin and 5-FU
compared with cells treated by allicin or 5-FU alone (P < 0.001
for both SK-Hep-1 and BEL-7402 cells; Fig. 4A and B).
Because excessive ROS accumulation may cause oxidative stress
and mitochondrial dysfunction, we evaluated mitochondrial func-
tion using JC-1 dye, an indicator of mitochondrial membrane po-
tential, by FCM analysis. The results showed that the mitochondrial
membrane potential (DJm) in cells co-treated by allicin and 5-FU
was more signiﬁcantly decreased compared with cells treated by
allicin or 5-FU alone (P < 0.001 for both SK-Hep-1 and BEL-7402
cells; Fig. 4C and D). Moreover, using ROS inhibitor NAC reversed
the increased sensitivity of HCC cells to 5-FU induced by allicin
(Fig. 4E). Taken together, these results indicated that allicin increase
the sensitivity of HCC cells to 5-FU-induced apoptosis through ROS-
mediated mitochondrial pathway.
5. Discussion
In this study, we investigate the role of allicin in sensitization of
HCC cells to 5-FU-inducing cell death in vitro and in vivo. Our results
showed the synergistic effect of subcytotoxic allicin and 5-FU on
inducing HCC cells death through ROS-mediated mitochondrial
pathway, which proposes the therapeutic value of allicin in HCC
chemotherapy.
Palliative chemotherapy has not been used routinely for pa-
tients with advanced HCC. Drug resistance and hepatic dysfunction
are the two major factors that limit the application of chemo-
therapy for HCC (14). Compared with other monotherapy, 5-FU has
been more acceptable because adequate doses can usually be
administered in the setting of hepatic dysfunction or jaundice (15).
Although response rate with 5-FU monotherapy has been low,
given in combination with other agents, response rates as high as
28% had been reported (15). And recently, FOLFOX regimen (5-FU,
oxaliplatin, and leucovorin) was found to have a higher objective
response rate, higher disease control rate and better median sur-
vival in HCC patients (16). Thus, treatments combined 5-FU with
other agents may play a role in therapies of advanced HCC.
Allicin has been reported that have anti-tumor effect in some
cancers through growth inhibition and apoptosis induction. In HCC,
allicin caused p53-mediated autophagic cell death (17). In
Fig. 2. Co-treatment of allicin and 5-FU signiﬁcantly inhibited HCC tumor growth in vivo. (A) Treatments with DMSO (as control), allicin, 5-FU or with a combination of allicin and 5-
FU were performed on twenty nude mice which were subcutaneously injected with SK-Hep-1 cells (1  107 per mouse) stably expressing GFP, and were randomly divided into four
groups (n ¼ 5 per group). Representative images of vivo xenograft tumors expressed GFP and tumors isolated from each group on day 21. (B) Continuous quantiﬁcation of tumor
volumes of each group during the experiment. (*P < 0.05, **P < 0.01) (C) The weight of xenograft tumors were showed as the mean ± SD of ﬁve tumors excised from each group.
(*P < 0.05). (D) TUNEL assay was used to evaluate DNA fragmentation of xenograft tumors after different administrations. (E) Quantitative analysis of TUNEL-positive cells (red) of
each group. Each value is presented as the mean ± SD of six random ﬁelds. (*P < 0.05, **P < 0.01).
X. Zou et al. / Journal of Pharmacological Sciences 131 (2016) 233e240 237glioblastoma, allicin induced apoptosis through mitochondrial
pathway of Bcl-2/Bax, the MAPK/ERK signaling pathway, and
antioxidant enzyme systems (18). In colon cancer, allicin enhanced
hypodiploid DNA content and increased capability of releasing cy-
tochrome C from mitochondria to cytosol, which resulted in
apoptotic cell death (19). In gastric cancer, allicin inhibited prolif-
eration and induced apoptosis through the p38 mitogen-activated
protein kinase/caspase-3 signaling pathway (20). In our study, we
also found that allicin had anti-proliferative effect in HCC cells.Meanwhile, allicin has hepatic protective effect. In experimental
animal studies, allicin showed the beneﬁcial effects against liver
damage caused by chemical poisons such as bromobenzene,
doxorubicin, and tamoxifen (6,21). Also allicin may contribute to
protection against liver injury induced by ethanol (22). Given its
hepatic beneﬁcial effect and antitumor activity, allicin is an ideal
enhancer to 5-FU-based chemotherapy regimen in HCC. In our data,
we provide the ﬁrst evidence about sensitive activation of allicin in
HCC cells, both in vitro and in vivo. Compared with the control,
Fig. 3. Apoptosis induced by allicin and 5-FU in HCC cells. (A) Flow cytometric analysis of cell apoptosis mediated by allicin and 5-FU in SK-Hep-1 and BEL-7402 cells. Cells were
treated with allicin (3 mg/ml), 5-FU (100 mg/ml) or combination for 48 h and were stained with Annexin V/PI. (B) Histogram showed the early apoptotic rate of cells in different
groups of these two cell lines from three independent experiments (*P < 0.05). (C) Cells were treated as described in A. Expression of proteins related in cell apoptosis was examined
by western blotting analysis. b-actin was used as a loading control.
X. Zou et al. / Journal of Pharmacological Sciences 131 (2016) 233e240238allicin, or 5-FU alone treatment groups, combined treatment with
allicin and 5-FU inhibited cell proliferation and induced cellular
apoptosis. Using CI equation, which allows for the evaluation of two
or more drugs at different concentrations and effect levels, we
demonstrated that allicin and 5-FU had the synergistic effect. Theseresults provided the evidence for the combination used of allicin
and 5-FU in clinical chemotherapy in the future.
The chemotherapy drug induced cell apoptosis is a complicated
process, which is mediated through various pathway and regulated
by lots of apoptotic related proteins (23). In our study, we looked
Fig. 4. Co-treatment of allicin and 5-FU affected the ROS-mediated mitochondrial pathway in HCC cells. (A) Dichloro-dihydro-ﬂuorescein diacetate assay was used to measure the
level of intracellular ROS. SK-Hep-1 and BEL-7402 cells treated with Allicin (3 mg/ml) and 5-FU (100 mg/ml), or combination for 48 h were prepared for detection. (B) Histogram
showed the mean of DCF ﬂuorescence intensity in each group. (**P < 0.01). (C) Mitochondrial transmembrane potential of cells treated with Allicin (3 mg/ml) and 5-FU (100 mg/ml),
or combination for 48 h was detected by Flow cytometry using JC-1 staining. (D) Histogram presented the percentage mean of P4 in each group from triplicate studies (*P < 0.05,
**P < 0.01). (E) SK-Hep-1 cells were treated with allicin (3 mg/ml), 5-FU (100 mg/ml), combination of allicin (3 mg/ml) and 5-FU (100 mg/ml), and combination of allicin (3 mg/ml), 5-FU
(100 mg/ml) and NAC (10 mM) for 48 h. Cell apoptosis was examined by western blotting analysis.
X. Zou et al. / Journal of Pharmacological Sciences 131 (2016) 233e240 239insight into the preliminary mechanism of the sensitive effect of
allicin in HCC cells. We suggested that allicin sensitized HCC cells to
5-FU-induced apoptosis through ROS-mediated mitochondrial
pathway. As we know, chemotherapy agents induce oxidativestress, and cause ROS generation (24). The accumulation of ROS in
themitochondria could inhibit the mitochondrial respiration chain,
which resulted in mitochondrial membrane rupture and apoptotic
cell death (25,26). In our study, we found that there was amoderate
X. Zou et al. / Journal of Pharmacological Sciences 131 (2016) 233e240240increase ROS level both in allicin and 5-FU single-agent groups.
However, when HCC cells were treated in combination, the ROS
production was dramatically increased. These results indicated the
synergistic effect of ROS generation in combined treatment.
Taken together, our study has demonstrated the growth inhi-
bition of allicin combined with 5-FU in HCC cells by inducing
apoptosis both in vitro and in vivo, and the analysis of enhanced
efﬁcacy indicates synergism. Combined treatment induced cellular
ROS production and decreased mitochondrial membrane potential,
followed by cellular apoptosis. These results provide the evidence
for the combination used of allicin and 5-FU as a novel chemo-
therapy regimen in HCC. Further clinical investigations are needed
to provide evidence on the efﬁcacy in HCC patients.
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